期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 61, 期 9, 页码 4203-4212出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b00357
关键词
-
资金
- FCT fund [SFRH/BD/96033/2013, SFRH/BPD/74491/2010]
- FEDER/COMPETE fund
- Fondazione Cariplo [2014-0672]
- COST action [CA15135]
- Societa Italiana di Biofisica e Biologia Molecolare (SIBBM)
- European Community [7551, 10205]
- Region Occitanie
- Foundation for Science and Technology (FCT), FEDER/COMPETE2020 [UID/QUI/00081/2015, POCI-01-0145-FEDER-006980]
Monoamine oxidase B (MAO-B) is a validated drug target for Parkinson's disease. Chromone derivatives were identified as novel potent and reversible MAO-B inhibitors, and herewith we report on a crystallographic and biochemical analysis to investigate their inhibition mechanism. The crystal structures of human MAO B in complex with three chromone analogs bearing different substituents on the exocyclic aromatic ring (determined at 1.6-1.8 A resolution) showed that they all bind in the active site cavity of the protein with the chromone moiety located in front of the FAD cofactor. These inhibitors form two hydrogen bonds with Tyr435 and Cys172 and perfectly fit the hydrophobic flat active site of human MAO-B. This is reflected in their tight-binding mechanism of inhibition with IC, values of 55, 17, and 31 nM for N-(3',4'dimethylphenyl)-4-oxo-4H-chromene-3-carboxamide (3) (1), N-(3 'chloropheny1)-4-oxo-4H-chrom ene-3-carboxamide (2), and N-(3'-fluoropheny1)-4-oxo-4H-chromene-3-carboxamide respectively. These compounds were also 1000-fold more effective than L-deprenyl in reducing the cellular levels of reactive oxygen species (ROS).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据